Transcript PowerPoint-presentation

Gränslös Innovation
Cristina Glad
Skånska Utvecklingsdagen
14 november 2005
Presentationen har inför publicering på skane.se rensats på bildelement pga utrymmesskäl.
14 samverkande Universitet
26 sjukhus varav 11 universitetssjukhus
Acumulated total of new biotech companies
(excluding medical technology and CROs)
160
140
120
100
New
80
Total
60
40
20
0
1997
1998
1999
Total no of start-ups: 110
Companies closed: 10
Mergers/Acquisitions: 5
2000
2001
2002
2003
Still existing 2005: 95
2004
Medicon Valley
Blockbusters
NovoPen
(insulin)
Novo Nordisk
Cipramil
(antidepressive)
Lundbeck
Turbuhaler
(powder inhalator)
AstraZeneca, Lund
with product
K108-LU5600
without -
K96-LU470
without - with -
K91-LU97
K92-LU50
K140-MT380
K132-MT278
Production
Product
Narrow research
Consultancydevelopment
& development
Wide-range research
& development
Swedish regions and Copenhagen - companies with an international market, excl. sales
K81-LP55
K72-LP320
K76-LP/LU380
Umeå
Uppsala
- Stockholm - Str-näs Linköping Gothenburg Others
Malmö/Lund
Copenhagen
K10-BP1231
Red=pharma; Pink= CRO; Yellow=medtech; Blue=biotech foods
Violet=pharma production (only); Brown=biotech/bioproduction
Medicon Valley
The European
biotech landscape
Source: Critical I Limited
Bioteknikbolagen I Europa är många men
har svårt att växa
Employees
80
”At the point at which Europe’s
companies ought to be taking off, most
of them appear to run out of financial
runway”
Source: Critical I Limited
60
40
20
0
0-2 y
3-5 y
Europe
6-10 y
USA
11-15 y
Antal anstälda
50
45
40
35
0 - 2 år
3 - 5 år
6 - 10 år
11 - 15 å
30
25
20
15
10
Intäkter m€
5
0
Sverige
12.0
10.0
8.0
6.0
4.0
2.0
0.0
Sverige
Danmark
Danmark
Getting venture
investment in European
biotechnology depends
on being in the right
place
Source: Critical I Limited
Capital to Biotech (Nov 2004-July 2005)
BioEtt (Nov-04)
Celltrix (Nov-04)
Symphogen (Nov-04)
Probi (IPO) (Dec-04)
CMC (Jan-05)
Ultrazonix (Jan-05)
Zealand Pharma (Feb-05)
LiPlasome (Mar-05)
SpectraCure (Mar-05)
TopoTarget (Mar-05)
Evolva (Mar-05)
Mitra Medical (Mar-05)
Acadia (Apr-05)
NsGene (May-05)
LifeCyclePharma (May-05)
Exiqon (May-05)
Pharmexa (publ.) (Jun-05)
ProstaLund (Jun-05)
TopoTarget (IPO) (Jul-05)
Medtentia (Jul-05)
Active Biotech (Jul-05)
0.6
1
TOTAL
60
21
4
14
3
26
6
2
15
14
3
30
4
15
17
40
3
31
1
18
>200 M€
Medicon Valley Academy
Initiative 1995 from universities and big pharma
companies
2000: Private membership based
non profit organisation
Universities, hospitals &
companies (260 members)
2 nations – 2 systems
Innovation Potential in Medicon Valley
Research
Technology Transfer
Companies
From BioScience to New Jobs in Medicon Valley - A
Medicon Valley Academy Strategic Report
300 million €
university research
3200 publications/yr
>150 inventions/yr
400 bio-companies
40,000 employees
Innovation Report 2004
Recommendations to improve the competitiveness of
Medicon Valley
1) More commercial know-how into Technology
Transfer Organisations
2) Regional TTO cooperation (!)
3) Funding for Proof - of- Concept studies
4) Seed investments across Øresund (!)
5) Tax incentives for the Young Biotech Industry
From BioScience to New Jobs in Medicon Valley - A
Medicon Valley Academy Strategic Report
Våra Svagheter
• Svårt att växa
• Brist på kapital
• Kompetens inom utveckling och
kommersialisering
• Svårt attrahera utländsk arbetskraft
• Skatter och avgifter
• Hjälpande infrastruktur
Vi måste vara attraktiva
Våra Styrkor
• Tillgång på högutbildad personal
• Tillgång på kompetens från andra företag
• Samarbete med akademin
• Innovationsklimatet inom akademin
– Lärarundantaget
– Holdingbolag, Innovationsbron etc.
Research infrastructure investments
•BMC (Lund)
Bio Medical Center
•CRC (Malmö)
Clinical Research Center
•BRIC (Copenhagen)
Biotech Research and
Innovation Center
Total investments 0.3-0.4 billion €
• SWEGENE (Lund)
Postgenomic RT Programme
in South Western Sweden
ESS?
LUND North Campus Area
Gambro
Sony Ericsson
Chemical Centre
Ideon
Science
Park
Cryo-EM
Microarray
Active Biotech
Genomic Ecology
University Hospital
LTH
Proteomics
Astra Zeneca
BMC
Transgenic core facility
Bioinformatics
500 m
MAX-lab
School of
Economics